SGMO
Sangamo Therapeutics, Inc.
Price Chart
Latest Quote
$0.17
+0.02 (+13.33%)
Current Price
| Previous Close | $0.15 |
| Open | $0.15 |
| Day High | $0.19 |
| Day Low | $0.15 |
| Volume | 606,089 |
Stock Information
| Shares Outstanding | 414.29M |
| Total Debt | $19.33M |
| Cash Equivalents | $27.59M |
| Revenue | $34.56M |
| Net Income | $-123.33M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $70.43M |
| EPS (TTM) | $-0.38 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $60.10M |
| Sales | $34.56M |
| Income | $-123.33M |
| Book/sh | $-0.05 |
| Cash/sh | $0.07 |
| Employees | 142 |
Financial Ratios
| Quick Ratio | 0.64 |
| Current Ratio | 0.70 |
Returns & Margins
| ROA | -94.37% |
| Gross Margin | -227.67% |
| Operating Margin | -2215.39% |
Ownership
| Insider Ownership | 1.76% |
| Institutional Ownership | 25.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 34.00 |
| P/S | 2.04 |
| P/B | -3.70 |
Analyst Data
| Recommendation | buy |
| Target Price | $1.67 |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 35.71 |
| ATR | nan |
| Shares Float | 370.04M |
| Short Float | 10.42% |
| Short Ratio | 5.55 |
| Volatility | 1.29 |
| Rel Volume | 0.18 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-15 | $nan | 606,089 |
| 2026-06-12 | $0.15 | 1,884,600 |
| 2026-06-11 | $0.15 | 2,100,500 |
| 2026-06-10 | $0.15 | 2,324,800 |
| 2026-06-09 | $0.15 | 5,023,500 |
| 2026-06-08 | $0.17 | 6,896,600 |
| 2026-06-05 | $0.22 | 2,040,300 |
| 2026-06-04 | $0.21 | 3,205,800 |
| 2026-06-03 | $0.22 | 2,108,800 |
| 2026-06-02 | $0.21 | 3,358,100 |
| 2026-06-01 | $0.21 | 2,536,800 |
| 2026-05-29 | $0.22 | 5,706,000 |
| 2026-05-28 | $0.21 | 1,232,700 |
| 2026-05-27 | $0.20 | 2,321,900 |
| 2026-05-26 | $0.19 | 5,848,700 |
| 2026-05-22 | $0.17 | 3,284,200 |
| 2026-05-21 | $0.16 | 2,905,500 |
| 2026-05-20 | $0.16 | 3,784,500 |
| 2026-05-19 | $0.15 | 4,434,800 |
| 2026-05-18 | $0.13 | 4,648,600 |
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc.  ALS and Frontotemporal Lobar Degeneration; Takeda  Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
đ° Latest News
Sangamo Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-15T12:30:00Z
Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial ...
GuruFocus.com âĸ 2026-05-15T05:02:56ZSangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-14T21:15:01Z
Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market
InvestorsHub âĸ 2026-04-29T14:45:25Z
Sangamo Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-31T12:30:00Z
Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2026-03-31T03:01:34ZSangamo Therapeutics Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-31T00:06:42Z
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-26T21:20:01Z
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-03-24T12:10:01Z
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
Zacks âĸ 2026-03-12T21:45:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $39,552,000 | $57,800,000 | $176,232,000 | $111,299,000 |
| Operating Revenue | $39,552,000 | $57,800,000 | $176,232,000 | $111,299,000 |
| Expenses | ||||
| Total Expenses | $147,556,000 | $156,248,000 | $295,224,000 | $312,580,000 |
| Other Income Expense | $-16,798,000 | $-1,173,000 | $-155,013,000 | - |
| Other Non Operating Income Expenses | $-3,563,000 | $4,348,000 | - | - |
| Net Non Operating Interest Income Expense | $1,302,000 | $1,513,000 | $11,102,000 | $9,432,000 |
| Operating Expense | $147,556,000 | $156,248,000 | $295,224,000 | $312,580,000 |
| General And Administrative Expense | $34,886,000 | $44,727,000 | $61,167,000 | $62,682,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-122,932,000 | $-97,941,000 | $-257,831,000 | $-192,278,000 |
| Net Interest Income | $1,302,000 | $1,513,000 | $11,102,000 | $9,432,000 |
| Interest Income | $1,302,000 | $1,513,000 | $11,102,000 | $9,432,000 |
| Normalized Income | $-109,763,175 | $-92,429,398 | $-105,808,555 | $-192,278,000 |
| Net Income From Continuing And Discontinued Operation | $-122,932,000 | $-97,941,000 | $-257,831,000 | $-192,278,000 |
| Total Operating Income As Reported | $-121,239,000 | $-103,969,000 | $-274,005,000 | $-201,281,000 |
| Net Income Common Stockholders | $-122,932,000 | $-97,941,000 | $-257,831,000 | $-192,278,000 |
| Net Income | $-122,932,000 | $-97,941,000 | $-257,831,000 | $-192,278,000 |
| Net Income Including Noncontrolling Interests | $-122,932,000 | $-97,941,000 | $-257,831,000 | $-192,278,000 |
| Net Income Continuous Operations | $-122,932,000 | $-97,941,000 | $-257,831,000 | $-192,278,000 |
| Pretax Income | $-123,500,000 | $-98,108,000 | $-262,903,000 | $-191,849,000 |
| Special Income Charges | $-13,235,000 | $-5,521,000 | $-155,013,000 | $0 |
| Interest Income Non Operating | $1,302,000 | $1,513,000 | $11,102,000 | $9,432,000 |
| Operating Income | $-108,004,000 | $-98,448,000 | $-118,992,000 | $-201,281,000 |
| Per Share | ||||
| Diluted EPS | $-0.44 | $-0.49 | $-1.48 | $-1.25 |
| Basic EPS | $-0.44 | $-0.49 | $-1.48 | $-1.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $-66,175 | $-9,398 | $-2,990,555 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-87,167,000 | $-83,566,000 | $58,213,000 | $-180,719,000 |
| Total Unusual Items | $-13,235,000 | $-5,521,000 | $-155,013,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-13,235,000 | $-5,521,000 | $-155,013,000 | $0 |
| Reconciled Depreciation | $7,602,000 | $9,361,000 | $22,192,000 | $20,562,000 |
| EBITDA (Bullshit earnings) | $-100,402,000 | $-89,087,000 | $-96,800,000 | $-180,719,000 |
| EBIT | $-108,004,000 | $-98,448,000 | $-118,992,000 | $-201,281,000 |
| Diluted Average Shares | $280,193,000 | $201,699,000 | $174,444,000 | $154,345,000 |
| Basic Average Shares | $280,193,000 | $201,699,000 | $174,444,000 | $154,345,000 |
| Diluted NI Availto Com Stockholders | $-122,932,000 | $-97,941,000 | $-257,831,000 | $-192,278,000 |
| Tax Provision | $-568,000 | $-167,000 | $-5,072,000 | $429,000 |
| Impairment Of Capital Assets | $13,235,000 | $5,521,000 | $155,013,000 | $0 |
| Research And Development | $112,670,000 | $111,521,000 | $234,057,000 | $249,898,000 |
| Selling General And Administration | $34,886,000 | $44,727,000 | $61,167,000 | $62,682,000 |
| Other Gand A | $34,886,000 | $44,727,000 | $61,167,000 | $62,682,000 |
| Minority Interests | - | - | $0 | $0 |
Fetched: 2026-04-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-14,268,000 | $22,770,000 | $82,887,000 | $206,677,000 |
| Total Assets | $59,745,000 | $101,635,000 | $165,320,000 | $562,509,000 |
| Total Non Current Assets | $23,915,000 | $49,944,000 | $70,992,000 | $262,182,000 |
| Other Non Current Assets | $871,000 | $2,379,000 | $2,765,000 | $18,523,000 |
| Non Current Accounts Receivable | $8,938,000 | $12,809,000 | $15,362,000 | - |
| Current Assets | $35,830,000 | $51,691,000 | $94,328,000 | $300,327,000 |
| Other Current Assets | $4,369,000 | $5,175,000 | $9,259,000 | $18,223,000 |
| Receivables | $10,513,000 | $4,598,000 | $4,067,000 | $4,472,000 |
| Taxes Receivable | $10,142,000 | $4,072,000 | $3,144,000 | - |
| Accounts Receivable | $371,000 | $526,000 | $923,000 | $3,678,000 |
| Cash Cash Equivalents And Short Term Investments | $20,948,000 | $41,918,000 | $81,002,000 | $277,632,000 |
| Cash And Cash Equivalents | $20,948,000 | $41,918,000 | $45,204,000 | $100,444,000 |
| Investmentin Financial Assets | - | - | $0 | $29,845,000 |
| Goodwill And Other Intangible Assets | - | - | $0 | $88,281,000 |
| Accrued Interest Receivable | - | - | $403,000 | $794,000 |
| Other Intangible Assets | - | - | - | $50,729,000 |
| Prepaid Assets | - | - | - | $18,223,000 |
| Debt | ||||
| Total Debt | $26,795,000 | $30,566,000 | $38,104,000 | $43,108,000 |
| Long Term Debt And Capital Lease Obligation | $25,093,000 | $26,253,000 | $33,515,000 | $38,986,000 |
| Current Debt And Capital Lease Obligation | $1,702,000 | $4,313,000 | $4,589,000 | $4,122,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $74,013,000 | $78,865,000 | $82,433,000 | $267,551,000 |
| Total Non Current Liabilities Net Minority Interest | $31,547,000 | $33,060,000 | $34,702,000 | $155,840,000 |
| Other Non Current Liabilities | $580,000 | $933,000 | $1,187,000 | $1,207,000 |
| Non Current Deferred Liabilities | $5,874,000 | $5,874,000 | $0 | $115,647,000 |
| Current Liabilities | $42,466,000 | $45,805,000 | $47,731,000 | $111,711,000 |
| Current Deferred Liabilities | $899,000 | $7,556,000 | $0 | $51,780,000 |
| Payables And Accrued Expenses | $22,144,000 | $19,367,000 | $34,224,000 | $34,303,000 |
| Payables | $14,437,000 | $15,485,000 | $15,259,000 | $22,418,000 |
| Accounts Payable | $14,437,000 | $15,485,000 | $15,259,000 | $22,418,000 |
| Non Current Deferred Taxes Liabilities | - | - | $0 | $6,270,000 |
| Equity | ||||
| Common Stock Equity | $-14,268,000 | $22,770,000 | $82,887,000 | $294,958,000 |
| Total Equity Gross Minority Interest | $-14,268,000 | $22,770,000 | $82,887,000 | $294,958,000 |
| Stockholders Equity | $-14,268,000 | $22,770,000 | $82,887,000 | $294,958,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,464,000 | $-7,530,000 | $-4,595,000 | $-8,404,000 |
| Other Equity Adjustments | $-1,464,000 | $-7,530,000 | $-4,595,000 | $-8,404,000 |
| Retained Earnings | $-1,627,249,000 | $-1,504,317,000 | $-1,406,376,000 | $-1,148,545,000 |
| Other | ||||
| Ordinary Shares Number | $350,688,142 | $212,837,679 | $178,133,548 | $166,793,320 |
| Share Issued | $350,688,142 | $212,837,679 | $178,133,548 | $166,793,320 |
| Tangible Book Value | $-14,268,000 | $22,770,000 | $82,887,000 | $206,677,000 |
| Invested Capital | $-14,268,000 | $22,770,000 | $82,887,000 | $294,958,000 |
| Working Capital | $-6,636,000 | $5,886,000 | $46,597,000 | $188,616,000 |
| Capital Lease Obligations | $26,795,000 | $30,566,000 | $38,104,000 | $43,108,000 |
| Total Capitalization | $-14,268,000 | $22,770,000 | $82,887,000 | $294,958,000 |
| Additional Paid In Capital | $1,610,938,000 | $1,532,489,000 | $1,492,077,000 | $1,450,239,000 |
| Capital Stock | $3,507,000 | $2,128,000 | $1,781,000 | $1,668,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $5,874,000 | $5,874,000 | $0 | $109,377,000 |
| Long Term Capital Lease Obligation | $25,093,000 | $26,253,000 | $33,515,000 | $38,986,000 |
| Current Deferred Revenue | $899,000 | $7,556,000 | $0 | $51,780,000 |
| Current Capital Lease Obligation | $1,702,000 | $4,313,000 | $4,589,000 | $4,122,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $17,721,000 | $14,569,000 | $8,918,000 | $21,506,000 |
| Current Accrued Expenses | $7,707,000 | $3,882,000 | $18,965,000 | $11,885,000 |
| Net PPE | $14,106,000 | $34,756,000 | $52,865,000 | $125,533,000 |
| Accumulated Depreciation | $-42,211,000 | $-39,818,000 | $-51,046,000 | $-36,530,000 |
| Gross PPE | $56,317,000 | $74,574,000 | $103,911,000 | $162,063,000 |
| Leases | $21,832,000 | $24,923,000 | $29,809,000 | $30,572,000 |
| Other Properties | $30,939,000 | $46,105,000 | $68,405,000 | $110,990,000 |
| Properties | $0 | $0 | $0 | $0 |
| Construction In Progress | - | $0 | $1,087,000 | $14,770,000 |
| Other Short Term Investments | - | $0 | $35,798,000 | $177,188,000 |
| Minority Interest | - | - | $0 | $0 |
| Investments And Advances | - | - | $0 | $29,845,000 |
| Goodwill | - | - | $0 | $37,552,000 |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-04-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-97,310,000 | $-67,406,000 | $-245,997,000 | $-243,798,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-97,208,000 | $-67,139,000 | $-224,842,000 | $-223,627,000 |
| Cash Flow From Continuing Operating Activities | $-97,208,000 | $-67,139,000 | $-224,842,000 | $-223,627,000 |
| Operating Gains Losses | - | $-1,026,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-102,000 | $-267,000 | $-21,155,000 | $-20,171,000 |
| Investing Cash Flow | $-102,000 | $37,524,000 | $153,531,000 | $59,285,000 |
| Cash Flow From Continuing Investing Activities | $-102,000 | $37,524,000 | $153,531,000 | $59,285,000 |
| Net Other Investing Changes | - | $1,951,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $73,668,000 | $28,991,000 | $15,106,000 | $84,869,000 |
| Financing Cash Flow | $70,749,000 | $28,377,000 | $14,588,000 | $84,660,000 |
| Cash Flow From Continuing Financing Activities | $70,749,000 | $28,377,000 | $14,588,000 | $84,660,000 |
| Net Other Financing Charges | $-3,263,000 | $-904,000 | $-1,453,000 | $-2,104,000 |
| Net Common Stock Issuance | $73,668,000 | $28,991,000 | $15,106,000 | $84,869,000 |
| Common Stock Issuance | $73,668,000 | $28,991,000 | $15,106,000 | $84,869,000 |
| Other | ||||
| End Cash Position | $20,948,000 | $43,418,000 | $46,704,000 | $101,944,000 |
| Beginning Cash Position | $43,418,000 | $46,704,000 | $101,944,000 | $180,372,000 |
| Effect Of Exchange Rate Changes | $4,091,000 | $-2,048,000 | $1,483,000 | $1,254,000 |
| Changes In Cash | $-26,561,000 | $-1,238,000 | $-56,723,000 | $-79,682,000 |
| Proceeds From Stock Option Exercised | $344,000 | $290,000 | $935,000 | $1,895,000 |
| Net Investment Purchase And Sale | $0 | $35,840,000 | $174,686,000 | $79,456,000 |
| Sale Of Investment | $0 | $35,840,000 | $234,237,000 | $356,847,000 |
| Net PPE Purchase And Sale | $-102,000 | $-267,000 | $-21,155,000 | $-20,171,000 |
| Purchase Of PPE | $-102,000 | $-267,000 | $-21,155,000 | $-20,171,000 |
| Change In Working Capital | $-4,224,000 | $4,507,000 | $-164,034,000 | $-82,319,000 |
| Change In Other Working Capital | $-6,657,000 | $13,430,000 | $-161,156,000 | $-90,390,000 |
| Change In Other Current Liabilities | $-4,399,000 | $-5,834,000 | $-5,057,000 | $-2,258,000 |
| Change In Payables And Accrued Expense | $5,847,000 | $-8,426,000 | $-7,101,000 | $13,348,000 |
| Change In Accrued Expense | $3,053,000 | $5,743,000 | $-12,690,000 | - |
| Change In Payable | $2,794,000 | $-14,169,000 | $5,589,000 | - |
| Change In Account Payable | $2,794,000 | $-14,169,000 | $5,589,000 | - |
| Change In Prepaid Assets | $830,000 | $4,384,000 | $10,256,000 | $-4,909,000 |
| Change In Receivables | $155,000 | $953,000 | $-976,000 | $1,890,000 |
| Changes In Account Receivables | $155,000 | $397,000 | $2,755,000 | $2,335,000 |
| Other Non Cash Items | $32,000 | $57,000 | $1,119,000 | - |
| Stock Based Compensation | $9,079,000 | $12,382,000 | $27,363,000 | $31,650,000 |
| Asset Impairment Charge | $13,235,000 | $5,521,000 | $155,013,000 | $0 |
| Depreciation Amortization Depletion | $7,602,000 | $9,361,000 | $22,192,000 | $20,562,000 |
| Depreciation And Amortization | $7,602,000 | $9,361,000 | $22,192,000 | $20,562,000 |
| Depreciation | $7,602,000 | $9,361,000 | $22,192,000 | $20,562,000 |
| Net Income From Continuing Operations | $-122,932,000 | $-97,941,000 | $-257,831,000 | $-192,278,000 |
| Purchase Of Investment | - | $0 | $-59,551,000 | $-277,391,000 |
| Amortization Of Securities | - | $-273,000 | $-2,329,000 | $-1,242,000 |
| Deferred Tax | - | $0 | $-6,335,000 | $0 |
| Deferred Income Tax | - | $0 | $-6,335,000 | $0 |
| Gain Loss On Investment Securities | - | $-1,026,000 | - | - |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-04-30